Valuation: Immutep Limited

Market Cap 60.42M 42.94M 37.53M 35.27M 32.19M 60.41M 4.11B 423M 163M 2.1B 161M 158M 6.76B P/E 2027 *
-2.41x
P/E 2028 * -3.73x
Enterprise Value 5.82M 4.14M 3.62M 3.4M 3.1M 5.82M 396M 40.79M 15.74M 202M 15.54M 15.2M 651M EV / Sales 2027 *
1.46x
EV / Sales 2028 * 8.86x
Free-Float
96.98%
Yield 2027 *
-
Yield 2028 * -
1 day-2.81%
1 week-14.29%
Current month-22.65%
1 month-26.68%
3 months-24.95%
6 months-28.27%
Current year-90.10%
1 week 0.28
Extreme 0.28
0.33
1 month 0.28
Extreme 0.28
0.4
Current year 0.28
Extreme 0.28
3.23
1 year 0.28
Extreme 0.28
3.53
3 years 0.28
Extreme 0.28
3.53
5 years 0.28
Extreme 0.28
5
10 years 0.28
Extreme 0.28
7.95
Manager TitleAgeSince
Chief Executive Officer 53 2014-07-08
Director of Finance/CFO - 2018-02-28
Chief Tech/Sci/R&D Officer - 2025-06-30
Director TitleAgeSince
Director/Board Member 53 2014-07-08
Chairman 76 2017-11-16
Director/Board Member 57 2014-02-11
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%-14.29% - - 41.99M
+2.55%+4.77%+4.07%+32.02% 46.68B
+0.08%+0.16%+43.79%+35.89% 44.42B
+0.66%+6.23%+8.96%+93.14% 41.58B
+0.05%-5.86%+334.27%+542.87% 41.32B
-1.60%+0.56%+10.84%+46.93% 30.14B
+0.96%+1.56%+26.52%+159.67% 17.42B
-0.01%-0.92% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.54B
-1.08%+12.11%-10.11% - 14.08B
Average +0.03%+1.67%+55.54%+136.35% 29.64B
Weighted average by Cap. +0.48%+0.96%+69.15%+144.54%

Financials

2027 *2028 *
Net sales 4M 2.84M 2.48M 2.34M 2.13M 4M 272M 28.02M 10.81M 139M 10.68M 10.44M 447M 3M 2.13M 1.86M 1.75M 1.6M 3M 204M 21.02M 8.11M 104M 8.01M 7.83M 336M
Net income -26.1M -18.55M -16.21M -15.24M -13.9M -26.09M -1.77B -183M -70.56M -906M -69.66M -68.14M -2.92B -30.47M -21.66M -18.93M -17.79M -16.23M -30.47M -2.07B -214M -82.39M -1.06B -81.34M -79.56M -3.41B
Net Debt -54.6M -38.81M -33.91M -31.87M -29.09M -54.59M -3.71B -383M -148M -1.89B -146M -143M -6.11B -33.83M -24.05M -21.01M -19.75M -18.02M -33.83M -2.3B -237M -91.47M -1.17B -90.3M -88.32M -3.78B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
26-09-22 US$0.2831 -2.81% 143,271
26-09-21 US$0.2913 +1.25% 357,654
26-09-18 US$0.2877 -9.21% 576,495
26-09-17 US$0.3169 -3.09% 245,306
26-09-16 US$0.3270 -1.00% 256,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.0410AUD
Average target price
0.1133AUD
Spread / Average Target
+176.41%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!